EchoGen (dodecafluoropentane)
- Region
- 🇪🇺 EU
- Active substance
- dodecafluoropentane
- Company
- Sonus Pharmaceuticals Ltd.
- Status
- Withdrawn
- Therapeutic area
- Echocardiography
- EU approval
- Fri 17 Jul 1998
- Application
- EMEA/H/C/000149
- ATC
- V08DA
- Official record
- www.ema.europa.eu
Indication
EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation. EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.
Regulatory milestones
No milestones recorded in the last year.
Follow EchoGen
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.